Followers | 197 |
Posts | 24669 |
Boards Moderated | 0 |
Alias Born | 04/03/2010 |
Friday, March 05, 2021 1:20:16 PM
And sometimes you see examples like the Wright Brothers vs Samuel Pierpont Langley, https://blogs.scientificamerican.com/observations/why-did-the-wright-brothers-succeed-when-others-failed/
Dr. Liau, and Prins seem to have been determined and are certainly well qualified for the task. And studying why others failed, is often the secret to success. Success often requires many failures leading to success. But those failures don't have to be your own failures.
And they are not the first to succeed, they could see who had succeeded, who didn't and what they did that led to their failure.
I personally have not studied every failure. Did they thnk one shot was enough, or one shot in an arm or directly into the tumor? Had they gotten the correct cells at the correct stage to do what they wanted the cell to do? Did they understand how antigens are picked up and what the state of the tumor itself should be for that to happen, whether outside of the body or inside of the body? What did they do to validate their treatment before trying it on humans or to manufacture it?
And what seem to be key issues, how did they understand the key ingredient, the autologous cells that they were extracting. Those cells have a complex life's journey where they do different things. Did they understand those details fully?
Much progress on cell therapies and cell programming has occurred in these last 2 decades. We've learned to take an adult blood cell, turn it into an embryonic like cell, and then into any cell in the human body, as if it is a baby cell. All of the science of that is studied and well known today in the field of cell therapy, and was being published over these last 2 decades or so.
We've learned to reprogram cells and how delicate the various states are to getting them to do one thing or another.
And, from decades and decades ago, we've studied how different factors, stimulants to the immune system, can help even to fight cancer. Did the others add those additional stimulants to their DC treatments?
There are billions of ways to do the same thing this complex, differently, and probably more than that.
So I know people want to ask that question, but really, often that is not the correct question... Why NWBO and not someone else? Why not? What did they have that was the secret to their success? I am sure that will be the main question people ask if and once DCVax is validated. I think they had a number of factors, and sometimes that is just fate that those elements all come together. Sometimes it is just that the key people just wanted to succeed that much more than others who tried, and they kept at it until they did succeed.
The link to the rest of this article is above:
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM